Amgen wins latest round in legal tussle over Enbrel patentsAmgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in Share XAmgen wins latest round in legal tussle over Enbrel patentshttps://pharmaphorum.com/news/amgen-wins-latest-round-in-legal-tussle-over-enbrel-patents/
SidekickHealth launches gamified meds management platform with PfizerPfizer and Nordic digital therapeutics firm SidekickHealth have launched a gamified digital medication management and lifestyle platform across Europe in a deal thought to Share XSidekickHealth launches gamified meds management platform with Pfizerhttps://pharmaphorum.com/news/sidekickhealth-launches-gamified-meds-management-platform-with-pfizer/
NodThera raises $55m in Series B round to trial inflammatory disease drugsThe Anglo-US biotech NodThera has raised $55 million in a second financing round as it prepares its inflammatory Share XNodThera raises $55m in Series B round to trial inflammatory disease drugshttps://pharmaphorum.com/news/nodthera-raises/
Gilead and Galapagos shares hit as filgotinib disappointsGilead and Galapagos’ late-stage trial of their ulcerative colitis drug filgotinib has hit its target – but shares Share XGilead and Galapagos shares hit as filgotinib disappointshttps://pharmaphorum.com/news/gilead-and-galapagos-shares-hit-as-filgotinib-disappoints/
California’s AMT is latest biotech aiming to go public in pandemic IPO crazeCalifornia’s Applied Molecular Transport has become the latest biotech to go for an IPO during the pandemic, aiming Share XCalifornia’s AMT is latest biotech aiming to go public in pandemic IPO crazehttps://pharmaphorum.com/news/californias-amt/
Janssen trials ultrasound-guided approach to treating Crohn’sIn the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to Share XJanssen trials ultrasound-guided approach to treating Crohn’shttps://pharmaphorum.com/news/janssen-trials-ultrasound-guided-approach-to-treating-crohns/
AbbVie’s CEO hails ‘exceptional’ psoriasis drug launch as Humira fadesThe bad news from AbbVie’s full year results was that inflammatory diseases blockbuster Humira “only” made around $19.2 Share XAbbVie’s CEO hails ‘exceptional’ psoriasis drug launch as Humira fadeshttps://pharmaphorum.com/news/abbvies-ceo-hails-exceptional-psoriasis-drug-launch-as-humira-fades/
AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie mergerAllergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy Share XAZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie mergerhttps://pharmaphorum.com/news/az-buys-back-rights-to-crohns-candidate-from-allergan-ahead-of-abbvie-merger/
Amgen strikes outcomes-based payment plan for Enbrel with AbarcaPharmacy benefit manager Abarca has announced a US reimbursement contract with Amgen for its Enbrel (etanercept) inflammatory diseases Share XAmgen strikes outcomes-based payment plan for Enbrel with Abarcahttps://pharmaphorum.com/news/amgen-strikes-outcomes-based-payment-plan-for-enbrel-with-abarca/
